BioWorld Asia

April 1, 2009

Intercell Gets Stock Boost as FDA Approves Ixiaro

Shares in Intercell AG received a significant boost Tuesday on news that the FDA approved its Japanese Encephalitis Virus (JEV) vaccine Ixiaro late Monday. (BioWorld International) Read More

BioVex Raises $40M to Fund Melanoma Vaccine Study

More Breast Cancer Genes to Boost Genetic Screening

EU Animal Directive Draws Ire from UK Researchers

Survey Points to Trouble Raising Funds in the UK

TcLand, Genedata Collaborate on Autoimmune Biomarkers

Newron Moves Ralfinamide into Pivotal Pain Trials

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

CT scan of brain showing subdural hematoma

FDA greenlights Medtronic Onyx subdural hematoma treatment

BioWorld MedTech

Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...